# United Airway Disease: An Evolving Concept? A Scoping Review of the Modern Literature on Integrated Treatment Approaches

**Authors:** Victor Alexandru, Alexia Manole, Ligia Salomea Groza, Felicia Manole

PMC · DOI: 10.3390/life16020220 · 2026-01-28

## TL;DR

This review explores treatment approaches that address both upper and lower airway diseases together, finding that integrated methods like biological therapies and nasal irrigation are effective and safe.

## Contribution

The paper provides a scoping review of modern literature on integrated treatment approaches for united airway disease.

## Key findings

- Biological treatments like dupilumab and non-biological methods are effective for upper and lower airway diseases.
- Integrated approaches show a good safety profile and improve patient outcomes.
- The review highlights the importance of considering combined treatment strategies for airway diseases.

## Abstract

Background: This scoping review screens modern literature in search of effective treatment approaches that target both upper and lower airway diseases. Methods: After the establishment of a research protocol, 227 potential articles were obtained through a logged search method. These were screened and narrowed down to 26 included articles. Data were extracted using a standardized data extraction form and were analyzed thematically and analytically. Results: The main integrated treatment approaches are biological (dupilumab was the most mentioned molecule) and non-biological (allergen immunotherapy, nasal saline irrigation, and endoscopic polypectomy). Data suggest that these approaches are effective in improving upper and lower airway outcomes and showcase a good safety profile. Conclusions: Patients with upper and lower airway diseases should benefit from integrated treatment approaches when possible.

## Full-text entities

- **Genes:** IL13RA2 (interleukin 13 receptor subunit alpha 2) [NCBI Gene 3598] {aka CD213A2, CT19, IL-13R, IL13BP}, IL4R (interleukin 4 receptor) [NCBI Gene 3566] {aka CD124, IL-4RA, IL4RA}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, TSLP (thymic stromal lymphopoietin) [NCBI Gene 85480], IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}
- **Diseases:** type 2 inflammatory diseases (MESH:C563310), PCC (OMIM:115700), Eczema (MESH:D004485), EGPA (MESH:D014890), eosinophilic (MESH:D017681), AR (MESH:D065631), nasal congestion (MESH:D009668), rhinoconjunctivitis (OMIM:613207), type 2 (MESH:D003924), rhinitis (MESH:D012220), NSAID (MESH:D055963), NERD (MESH:D018450), allergic (MESH:D004342), type 2 diseases (MESH:C536595), chronic rhinosinusitis (MESH:D000092562), atopic dermatitis (MESH:D003876), eosinophilic pneumonia (MESH:D011657), Disease (MESH:D004194), injury to (MESH:D014947), 2 inflammation (MESH:D007249), respiratory disease (MESH:D012140), ESS (MESH:D012852), secretory otitis media (MESH:D010034), asthma (MESH:D001249), eosinophilia (MESH:D004802), respiratory (MESH:D012131), Airway Disease (MESH:D029424), upper airway diseases (MESH:C000726767), CRSwNP (MESH:D009298), CRS (MESH:D003398)
- **Chemicals:** LABA (-), methacholine (MESH:D016210), mepolizumab (MESH:C434107), Dupilumab (MESH:C582203), omalizumab (MESH:D000069444), triamcinolone (MESH:D014221), benralizumab (MESH:C571386), tezepelumab (MESH:C000622721), E (MESH:D004540), reslizumab (MESH:C515492), nitric oxide (MESH:D009569), SABA (MESH:C046122)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941778/full.md

---
Source: https://tomesphere.com/paper/PMC12941778